Related Experiment Videos
Lipid-lowering drugs: are adverse effects predictable and reversible?
Antonio Muscari1, Giovanni M Puddu, Paolo Puddu
1Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Italy. amuscari@med.unibo.it
Cardiology
|June 22, 2002
Summary
Statins and fibrates can cause serious adverse effects, including myopathy and liver issues, especially when combined. Close patient monitoring is crucial to prevent complications from these lipid-lowering drugs.
Area of Science:
- Pharmacology
- Clinical Medicine
Background:
- Statins and fibrates are widely used lipid-lowering agents.
- Both drug classes are associated with potential adverse events, particularly when used concurrently.
Purpose of the Study:
- To review the adverse effects of statins and fibrates.
- To highlight the risks associated with combination therapy.
Main Methods:
- Review of literature on statin and fibrate adverse events.
- Analysis of drug metabolism pathways and predisposing factors.
Main Results:
- Statins metabolized by CYP enzymes (3A4, 2C9, 2C19) are linked to adverse events.
- Factors like age, sex, and renal insufficiency increase risk.
- Common complications include myopathy, rhabdomyolysis, and hepatic dysfunction.
- Fibrates can cause liver enzyme elevations, GI issues, and rhabdomyolysis.
- Combination therapy poses significant risks and should be avoided.
Conclusions:
- Combination therapy with statins and fibrates can lead to severe complications.
- Patient monitoring and education are essential for managing adverse outcomes.